Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
Incyte (Nasdaq:INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1 study of INCB001158, an arginase inhibitor being developed with Calithera Biosciences, alone and in combination with pembrolizumab as a treatment for advanced or metastatic solid tumors, will also be presented.
“Incyte is committed to advancing treatments that have the potential to address areas of high unmet need and we look forward to sharing data on our investigational therapies with the oncology community at ESMO 2019,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data from the Phase 2 FIGHT-202 study assessing pemigatinib as a potential treatment for cholangiocarcinoma are encouraging and may represent an important step forward for patients in urgent need of effective treatment options.”
Abstracts will be available on the ESMO Congress website at https://www.esmo.org/Conferences/ESMO-Congress-2019.
FIGHT-202: a Phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (Abstract #2550, proffered paper session)
- Friday, September 27, 2019 from 3:00 p.m. CEST to 3:15 p.m. CEST (9 a.m. ET to 9:15 a.m. ET) in Madrid Auditorium (Hall 2)
Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (Adv/Met) solid tumors (Abstract #1621, oral abstract session)
- Sunday, September 29, 2019 from 4:54 p.m. CEST to 5:06 p.m. CEST (10:54 a.m. ET to 11:06 a.m. ET) in Malaga Auditorium (Hall 5)
Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial (Abstract #2078, poster session)
- Sunday, September 29, 2019 from 12:00 p.m. CEST to 1:00 p.m. CEST (6:00 a.m. ET to 7:00 a.m. ET) in Poster Area (Hall 4)
Full session details and data presentation listings for ESMO 2019 can be found at: https://cslide.ctimeetingtech.com/esmo2019/attendee.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development programs for pemigatinib and an arginase inhibitor as monotherapy and in combination with pembrolizumab and the potential of such programs, including the potential for pemigatinib to treat cholangiocarcinoma, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2019. The Company disclaims any intent or obligation to update these forward-looking statements.
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lega Serie A and Math&Sport Presented the “Football Virtual Coach”18.11.2019 12:05:00 EET | Press release
Lega Serie A and Math&Sport presented today during the “Barça Sports Technology Symposium” in Barcelona the “Football Virtual Coach”, an innovative system that allows technical staff to optimize the performance of their teams through real-time tactical analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005201/en/ Starting from the second round of the 2019/2020 Serie A TIM the Lega Serie A will equip all the benches of a tablet with the Football Virtual Coach installed. It has been developed by Math&Sport, an Italian incubated startup (PoliHub – Polytechnic University of Milan). The Virtual Football Coach will analyse data coming from video tracking systems to provide, thanks to Artificial Intelligence, the whole technical staff with the most strategic indications to optimize tactics or countering the opponent’s strategy. The coaches will be able to customize the information based on their strategies. “The Serie A
Cooper Tire Europe Launches Extensive New Rally Tire Range for Tarmac, Classic Tarmac, Gravel and Mud and Snow Applications18.11.2019 12:00:00 EET | Press release
Cooper Tire Europe today launched an extensive new rally tire range, providing ultra-high performance and reliability across numerous applications and levels of rallying competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005135/en/ Cooper Tire Europe today launched an extensive new rally tire range, providing ultra-high performance and reliability across numerous applications and levels of rallying competition. (Photo: Business Wire) Developed and manufactured by Cooper Tire Europe, the new range covers tarmac, classic tarmac, gravel and mud and snow (M+S) applications with the following products: the Cooper Discoverer Tarmac DT1, the Cooper Discoverer Tarmac DT02, the Cooper Rally Classic Tarmac CT01, the Cooper Discoverer Gravel DG1, the Cooper M+S and the Cooper M+S Evo. Within the core range of six tire patterns, 13 different sizes are available – covering 13 to 18 inch rims. The Cooper M+S and Cooper M+S
IDEMIA Launches the Very First Metal Card in Belgium, With Nagelmackers Bank18.11.2019 10:52:00 EET | Press release
IDEMIA supplies the very first metal payment card in Belgium, which was launched mid-November for Nagelmackers Bank's Elite and Prestige customers. With this new payment card, Nagelmackers seeks to give its Elite and Prestige customers a top-of-the-range free service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191117005094/en/ (Photo: Business Wire) The metal card market is booming and is becoming increasingly popular among wealthy clients. According to a recent worldwide poll1, metal cards are the card of choice for 75% of affluent consumers worldwide. This first launch of metal cards in the Belgian market is now set to boost the growth of metal cards in Europe. Is it because the metal card is heavier than other bank cards? Or because of its distinctive sound when put on a table? Whatever the reason, more and more banks use premium metal cards to market high-end services as a distinguishing feature. Designed by IDEMIA w
A 360° Protection Offer of Major Events and Sensitive Sites Presented by Bertin, Exensor and Cnim Air Space at Milipol Paris 201918.11.2019 10:30:00 EET | Press release
Leading players in the Defense and Security sector in France & abroad, Bertin Technologies, Exensor, Bertin IT and CNIM Air Space (CNIM Group companies) will be exhibiting at the GICAT Pavilion to present their complementary operational solutions dedicated to the protection of people and the surveillance of the interests of States and communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191117005033/en/ A 360° protection offer of major events and sensitive sites presented by Bertin, Exensor and Cnim Air Space at Milipol Paris 2019. (Graphic: Bertin) This event will be the opportunity to highlight our news: - New contract: Exensor & Siltec announce the signature of a major contract with the Polish Ministry of Defense to supply 116 Unattended Ground Sensor (UGS) systems - CNIM Air Space, formerly Airstar Aerospace, joined the CNIM Group in March 2019. Thanks to its experience gained in projects designed for the benefit
Bempedoic Acid Lowers LDL-Cholesterol without Adversely Impacting Glycaemic Control in Pooled Analyses of Phase 3 Trials Presented at the American Heart Association 2019 Scientific Sessions18.11.2019 10:00:00 EET | Press release
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the results of two pooled analyses from four Phase 3 clinical trials of bempedoic acid which were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA). One presentation highlighted that bempedoic acid reduced haemoglobin A1c (HbA1c) by 0.19% versus placebo in patients with diabetes at 12 weeks.2 HbA1c is a standard measure of glycaemic control used in diabetes management. The analysis also showed that patients on bempedoic acid had fewer instances of new-onset diabetes as well as hyperglycaemia than those on placebo.2 The pooled analysis suggests that bempedoic acid does not have an adverse impact on glycaemic control in patients with and without diabetes when added to a stable background of lipid lowering ther
DaraPay Announces Strategic Partnership with Chinese Tech Giant- Alipay18.11.2019 06:26:00 EET | Press release
DaraPay, the leading mobile E-wallet and payment service providers, today announces its partnership with Alipay, world’s leading payment and lifestyle platform operated by Ant Financial. With this partnership, Chinese tourists can scan and pay with their Alipay app at all DaraPay merchants with more than 3,000 outlets in Phnom Penh, Kandal, Kampong Cham, Siem Reap and Battambang province. Alipay serves over 1.2 billion users together with its regional partners and is the preferred payment method of Chinese tourists1. Through this strategic partnership, the two partners are looking to integrate their respective systems with one another and offer the market a flexible, on-demand digital payment solution through which Chinese tourists can conveniently use during their visit to Cambodia. With the system now in place, Alipay users are no longer required to withdraw cash or perform cross-app money transfer to make payments across the Kingdom. They can simply complete their purchases by scann
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom